Who owns SAB BIOTHERAPEUTICS INC?
- Ticker: SABS
- CUSIP Number: 78397t202
Tip: Access positions for across all investors
Analyze quarterly positions in Sab Biotherapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Sab Biotherapeutics stock
Who bought or sold SAB BIOTHERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Vivo Capital | 11M | $44M | 0% | Mar 2026 |
|
| Perceptive Advisors | 6.4M | $25M | 701% | Mar 2026 |
|
| Commodore Capital | 4.4M | $17M | 0% | Mar 2026 |
|
| RA Capital Management | 4.4M | $17M | 0% | Mar 2026 |
|
| Balyasny Asset Management | 3.8M | $14M | 691% | Mar 2026 |
|
| Millennium Management | 3.0M | $12M | 836% | Mar 2026 |
|
| Woodline Partners | 2.9M | $11M | 0% | Mar 2026 |
|
| Vanguard Capital Management | 2.5M | $9.6M | 100% | Mar 2026 |
|
| Sessa Capital IM | 2.2M | $8.4M | 0% | Mar 2026 |
|
| Vanguard Group | 1.8M | $6.9M | 405% | Dec 2025 |
|
| Boothbay Fund Management | 1.5M | $5.7M | 100% | Mar 2026 |
|
| Ameriprise Financial | 1.5M | $5.7M | 420% | Mar 2026 |
|
| Ensign Peak Advisors | 1.4M | $5.3M | 100% | Mar 2026 |
|
| Soleus Capital Management | 1.1M | $4.0M | 100% | Mar 2026 |
|
| Propel Bio Management | 1.0M | $3.9M | 55% | Mar 2026 |
|
| Leucadia National Corporation | 903k | $3.5M | 56% | Mar 2026 |
|
| Blackstone Group | 860k | $3.3M | -60% | Mar 2026 |
|
| Monashee Investment Management | 500k | $1.9M | 100% | Mar 2026 |
|
| AWM Investment Company | 400k | $1.5M | 100% | Mar 2026 |
|
| Stempoint Capital | 375k | $1.4M | 156% | Mar 2026 |
|
| HB Wealth Management | 308k | $1.2M | 0% | Mar 2026 |
|
| Geode Capital Management | 302k | $1.2M | 153% | Mar 2026 |
|
| BlackRock | 301k | $1.2M | 1648% | Mar 2026 |
|
| Seven Grand Managers | 275k | $1.1M | 100% | Mar 2026 |
|
| Marshall Wace | 237k | $884k | 100% | Dec 2025 |
|
| Vanguard Fiduciary Trust | 198k | $757k | 100% | Mar 2026 |
|
| Simplify Asset Management | 187k | $717k | -10% | Mar 2026 |
|
| Two Sigma Investments | 181k | $694k | 100% | Mar 2026 |
|
| Goldman Sachs Group | 114k | $436k | 122% | Mar 2026 |
|
| Seven Fleet Capital Management | 100k | $383k | 100% | Mar 2026 |
|
| Jane Street | 82k | $316k | 100% | Mar 2026 |
|
| Persistent Asset Partners | 70k | $267k | 252% | Mar 2026 |
|
| Citadel Advisors | 70k | $267k | 294% | Mar 2026 |
|
| Kestra Advisory Services | 62k | $237k | 435% | Mar 2026 |
|
| Brevan Howard Capital Management | 59k | $227k | 100% | Mar 2026 |
|
| Bank of America Corporation | 56k | $213k | 100% | Mar 2026 |
|
| Pathstone Holdings | 51k | $194k | 0% | Mar 2026 |
|
| UBS Group | 47k | $179k | 530% | Mar 2026 |
|
| Commonwealth Equity Services | 47k | $178k | 100% | Mar 2026 |
|
| Citigroup | 37k | $141k | 100% | Mar 2026 |
|
| Qube Research & Technologies | 31k | $117k | 100% | Dec 2025 |
|
| OMERS Administration Corporation | 30k | $114k | -29% | Mar 2026 |
|
| Verition Fund Management | 27k | $101k | 100% | Dec 2025 |
|
| Colony | 19k | $72k | 100% | Dec 2025 |
|
| First PREMIER Bank | 19k | $73k | 0% | Mar 2026 |
|
| Northern Trust | 16k | $61k | 44% | Dec 2025 |
|
| Diametric Capital | 16k | $62k | 100% | Mar 2026 |
|
| Hudson Bay Capital Management | 16k | $62k | 100% | Mar 2026 |
|
| Catalyst Funds Management Pty | 15k | $58k | 100% | Mar 2026 |
|
| Fifth Lane Capital | 15k | $56k | 100% | Dec 2025 |
|
| State Street Corporation | 13k | $49k | 100% | Dec 2025 |
|
| Morgan Stanley | 12k | $46k | 179% | Mar 2026 |
|
| Vanguard Global Advisers | 12k | $45k | 100% | Mar 2026 |
|
| Scientech Research | 11k | $41k | 100% | Mar 2026 |
|
| State of Wyoming | 7.9k | $30k | -12% | Mar 2026 |
|
| Pnc Financial Services | 7.7k | $30k | 100% | Mar 2026 |
|
| Plante Moran Financial Advisors | 5.9k | $23k | 100% | Mar 2026 |
|
| Advisor Group Holdings | 5.0k | $19k | 4% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 889.00 | $3.4k | 100% | Mar 2026 |
|
| MAI Wealth Advisors | 217.00 | $831.999700 | 0% | Mar 2026 |
|
| Gs Investments | 200.00 | $766.000000 | 0% | Mar 2026 |
|
| Caitong International Asset Management | 161.00 | $617.000300 | 100% | Mar 2026 |
|
| Harbour Investments | 50.00 | $192.000000 | 0% | Mar 2026 |
|
| Royal Bank of Canada | 1.00 | $0 | 100% | Mar 2026 |
|
Who sold out of Sab Biotherapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| ExodusPoint Capital Management | Dec 2025 | 86k | $322k |
| Renaissance Technologies | Sep 2025 | 81k | $163k |
| ADAR1 Capital Management | Dec 2025 | 26k | $99k |
| Virtu Financial | Sep 2025 | 20k | $40k |
| Caxton | Dec 2025 | 11k | $39k |
| Tower Research Capital | Sep 2025 | 1.6k | $3.1k |
| Jpmorgan Chase & Co | Sep 2025 | 87.00 | $175.000500 |
| SBI Securities | Dec 2025 | 50.00 | $187.000000 |